Lukasz Szczerbinski, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prediabetic State | 3 | 2022 | 545 | 1.160 |
Why?
|
Bariatrics | 2 | 2022 | 36 | 0.970 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2024 | 12145 | 0.850 |
Why?
|
Exercise | 4 | 2024 | 5872 | 0.700 |
Why?
|
Anti-Obesity Agents | 1 | 2023 | 227 | 0.690 |
Why?
|
Thyroxine | 1 | 2023 | 666 | 0.680 |
Why?
|
Muscle, Skeletal | 3 | 2024 | 4947 | 0.620 |
Why?
|
Multifactorial Inheritance | 3 | 2024 | 1381 | 0.590 |
Why?
|
Poland | 6 | 2024 | 198 | 0.540 |
Why?
|
Metabolomics | 2 | 2022 | 1658 | 0.500 |
Why?
|
Obesity, Morbid | 2 | 2022 | 1277 | 0.470 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2024 | 3416 | 0.400 |
Why?
|
Adipose Tissue | 1 | 2021 | 3309 | 0.330 |
Why?
|
Mitochondria | 1 | 2021 | 3620 | 0.300 |
Why?
|
Sulfonylurea Compounds | 2 | 2020 | 219 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 6 | 2024 | 17889 | 0.290 |
Why?
|
Electronic Health Records | 1 | 2024 | 4813 | 0.280 |
Why?
|
Gastrectomy | 3 | 2022 | 671 | 0.280 |
Why?
|
Obesity | 6 | 2023 | 12937 | 0.240 |
Why?
|
Apigenin | 1 | 2024 | 16 | 0.240 |
Why?
|
Cell Respiration | 2 | 2021 | 201 | 0.230 |
Why?
|
Algorithms | 1 | 2024 | 14023 | 0.230 |
Why?
|
Case-Control Studies | 5 | 2024 | 22157 | 0.220 |
Why?
|
Endocrine System | 1 | 2023 | 114 | 0.210 |
Why?
|
Prolactin | 1 | 2023 | 625 | 0.190 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2021 | 129 | 0.190 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2022 | 353 | 0.180 |
Why?
|
Anthracyclines | 1 | 2022 | 285 | 0.180 |
Why?
|
Phosphatidylcholines | 1 | 2022 | 404 | 0.170 |
Why?
|
Mitochondria, Liver | 1 | 2021 | 190 | 0.170 |
Why?
|
Remote Consultation | 1 | 2022 | 237 | 0.170 |
Why?
|
Thyrotropin | 1 | 2023 | 834 | 0.170 |
Why?
|
Mitochondria, Muscle | 1 | 2021 | 172 | 0.170 |
Why?
|
Flavonoids | 1 | 2022 | 444 | 0.170 |
Why?
|
Mitochondria, Heart | 1 | 2021 | 229 | 0.170 |
Why?
|
Body Mass Index | 7 | 2022 | 12951 | 0.160 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2022 | 269 | 0.160 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2022 | 1535 | 0.150 |
Why?
|
Metabolome | 2 | 2021 | 989 | 0.150 |
Why?
|
Genome-Wide Association Study | 5 | 2024 | 12670 | 0.140 |
Why?
|
Doxorubicin | 1 | 2024 | 2224 | 0.140 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2017 | 144 | 0.140 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2017 | 152 | 0.140 |
Why?
|
Estradiol | 1 | 2023 | 1936 | 0.130 |
Why?
|
Hydrocortisone | 1 | 2023 | 1818 | 0.120 |
Why?
|
Tandem Mass Spectrometry | 1 | 2022 | 1186 | 0.120 |
Why?
|
Humans | 30 | 2024 | 761098 | 0.120 |
Why?
|
Male | 18 | 2024 | 360675 | 0.120 |
Why?
|
Prevalence | 2 | 2024 | 15717 | 0.120 |
Why?
|
RNA, Viral | 1 | 2023 | 2839 | 0.120 |
Why?
|
Metabolic Diseases | 1 | 2021 | 680 | 0.120 |
Why?
|
NAD | 1 | 2019 | 611 | 0.120 |
Why?
|
Exercise Therapy | 1 | 2021 | 922 | 0.120 |
Why?
|
Weight Loss | 2 | 2023 | 2680 | 0.120 |
Why?
|
Microcirculation | 1 | 2019 | 1280 | 0.110 |
Why?
|
Middle Aged | 12 | 2024 | 220835 | 0.110 |
Why?
|
Adult | 12 | 2024 | 221083 | 0.100 |
Why?
|
Testosterone | 1 | 2023 | 2472 | 0.100 |
Why?
|
Hyperuricemia | 1 | 2014 | 222 | 0.100 |
Why?
|
Energy Metabolism | 2 | 2021 | 2877 | 0.100 |
Why?
|
Proteomics | 1 | 2024 | 3836 | 0.090 |
Why?
|
Lipids | 1 | 2022 | 3330 | 0.090 |
Why?
|
Blood Glucose | 3 | 2020 | 6390 | 0.090 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14607 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2017 | 883 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3951 | 0.090 |
Why?
|
Female | 16 | 2024 | 392458 | 0.090 |
Why?
|
Laparoscopy | 1 | 2020 | 2030 | 0.080 |
Why?
|
Homeostasis | 1 | 2019 | 3318 | 0.080 |
Why?
|
Pandemics | 3 | 2022 | 8663 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3086 | 0.070 |
Why?
|
Diet | 2 | 2024 | 8047 | 0.070 |
Why?
|
MicroRNAs | 1 | 2022 | 3758 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10552 | 0.060 |
Why?
|
Telemedicine | 1 | 2022 | 3051 | 0.060 |
Why?
|
Skin | 1 | 2019 | 4473 | 0.060 |
Why?
|
Disease Progression | 1 | 2021 | 13506 | 0.060 |
Why?
|
Cohort Studies | 3 | 2022 | 41486 | 0.060 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2024 | 126 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9416 | 0.060 |
Why?
|
Genotype | 3 | 2023 | 12983 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2024 | 15915 | 0.050 |
Why?
|
Hydroxyl Radical | 1 | 2022 | 82 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5841 | 0.050 |
Why?
|
Quercetin | 1 | 2022 | 97 | 0.050 |
Why?
|
Biological Availability | 1 | 2022 | 389 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11856 | 0.050 |
Why?
|
Adolescent | 5 | 2022 | 88271 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8236 | 0.050 |
Why?
|
Child, Preschool | 2 | 2022 | 42217 | 0.050 |
Why?
|
Protein Carbonylation | 1 | 2021 | 28 | 0.050 |
Why?
|
Citrate (si)-Synthase | 1 | 2021 | 48 | 0.050 |
Why?
|
Age Factors | 3 | 2024 | 18385 | 0.040 |
Why?
|
Drug Synergism | 1 | 2024 | 1756 | 0.040 |
Why?
|
Ubiquinone | 1 | 2021 | 183 | 0.040 |
Why?
|
Risk Factors | 3 | 2024 | 74219 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2022 | 677 | 0.040 |
Why?
|
Swine, Miniature | 1 | 2021 | 961 | 0.040 |
Why?
|
Aged | 4 | 2024 | 169266 | 0.040 |
Why?
|
Gene Frequency | 1 | 2024 | 3603 | 0.040 |
Why?
|
Luminescent Measurements | 1 | 2019 | 340 | 0.040 |
Why?
|
Hydrogen Peroxide | 1 | 2021 | 731 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20981 | 0.030 |
Why?
|
Pharmacogenetics | 1 | 2020 | 675 | 0.030 |
Why?
|
United States | 1 | 2024 | 72337 | 0.030 |
Why?
|
Forearm | 1 | 2019 | 427 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2019 | 1178 | 0.030 |
Why?
|
Child | 2 | 2022 | 80134 | 0.030 |
Why?
|
Epigenomics | 1 | 2021 | 943 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 2019 | 1498 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22125 | 0.030 |
Why?
|
Anthropometry | 1 | 2019 | 1338 | 0.030 |
Why?
|
Antioxidants | 1 | 2022 | 1667 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 2227 | 0.030 |
Why?
|
Proteome | 1 | 2024 | 1856 | 0.030 |
Why?
|
Cell Survival | 1 | 2024 | 5776 | 0.030 |
Why?
|
Hematologic Tests | 1 | 2014 | 239 | 0.030 |
Why?
|
Fasting | 1 | 2019 | 1603 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2731 | 0.020 |
Why?
|
Cell Movement | 1 | 2024 | 5195 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4341 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5909 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3728 | 0.020 |
Why?
|
Time Factors | 2 | 2024 | 39953 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2021 | 3114 | 0.020 |
Why?
|
Triglycerides | 1 | 2017 | 2457 | 0.020 |
Why?
|
Genetic Variation | 1 | 2024 | 6565 | 0.020 |
Why?
|
Health Status | 1 | 2022 | 4077 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 806 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8639 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10421 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4642 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16947 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4386 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4572 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16572 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2020 | 64670 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59199 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15308 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8130 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23415 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26068 | 0.010 |
Why?
|
Animals | 2 | 2021 | 168083 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 80673 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54419 | 0.010 |
Why?
|